In the newly released Lung-RADS 2022 classification system for computed tomography (CT) lung cancer screening, the American College of Radiology (ACR) has noted a variety of updates including new classification criteria for atypical pulmonary cysts and airway nodules, time intervals for nodule growth and a new stepped management approach for Lung-RADS categories 3 and 4A.
The American College of Radiology (ACR) has unveiled Lung-RADS 2022 with a number of key updates and changes in classification criteria and management considerations for lung nodules diagnosed via computed tomography (CT) screening.
Here are seven takeaways from the updated classification system.
1. In regard to atypical pulmonary cysts, the ACR said Lung-RADS category 4B is applicable for growing multilocular cysts, multilocular cysts with increased density or loculation, and growing thick-walled cysts.
2. One may apply the Lung-RADS v1.1 perifissural nodule composition and size criteria to all juxtapleural nodules. For solid juxtapleural nodules that have smooth margins, triangular, ovoid or tentiform in shape, and have a mean diameter less than or equal to 10 mm, radiologists would note these nodules as Lung-RADS category 2, according to the ACR.
3. For airway nodules, the Lung-RADS 2022 classification notes that solid endobronchial or endotracheal nodules that are segmental or more proximal would fall under Lung-RADS category 4A. When a three-month low-dose CT (LDCT) exam reveals persistent 4A endobronchial or endotracheal nodules, the ACR said these nodules should be reclassified as Lung-RADS category 4B. In these cases, the Lung-RADS 2022 classification recommends appropriate diagnostic workup and clinical evaluation for a possible bronchoscopy.
4. For partly solid or solid nodules that increase in size over multiple screening exams but not to the extent of surpassing a 1.5 mm increase during a 12-month period, the ACR said these lesions are suspicious and warrant Lung-RADS 4B classification with diagnostic evaluation recommended.
5. For ground-glass nodules that demonstrate growth over multiple screening exams during a one-year period without exceeding a 1.5 mm size change, the Lung-RADS 2022 document recommends Lung-RADS category 2 classification until subsequent findings, such as a solid nodule component, suggest otherwise.
6. When a six-month follow-up LDCT exam shows stable or decreased size of Lung-RADS 3 nodules, the Lung-RADS 2022 document recommends reclassifying the nodules as Lung-RADS category 2 with a subsequent LDCT exam to be performed one year from the date of the current exam.
7. When a three-month follow-up LDCT exam shows stable or decreased size of Lung-RADS 4A nodules, the Lung-RADS 2022 document recommends reclassifying the nodules as Lung-RADS category 3 with a subsequent LDCT exam to be performed six months from the date of the current exam.
For additional information on Lung-RADS 2022, see https://www.acr.org/-/media/ACR/Files/RADS/Lung-RADS/Lung-RADS-2022.pdf
Photon-Counting Computed Tomography: Eleven Takeaways from a New Literature Review
May 27th 2025In a review of 155 studies, researchers examined the capabilities of photon-counting computed tomography (PCCT) for enhanced accuracy, tissue characterization, artifact reduction and reduced radiation dosing across thoracic, abdominal, and cardiothoracic imaging applications.
Can AI Predict Future Lung Cancer Risk from a Single CT Scan?
May 19th 2025In never-smokers, deep learning assessment of single baseline low-dose computed tomography (CT) scans demonstrated a 79 percent AUC for predicting lung cancer up to six years later, according to new research presented today at the American Thoracic Society (ATS) 2025 International Conference.
Can Emerging AI Software Offer Detection of CAD on CCTA on Par with Radiologists?
May 14th 2025In a study involving over 1,000 patients who had coronary computed tomography angiography (CCTA) exams, AI software demonstrated a 90 percent AUC for assessments of cases > CAD-RADS 3 and 4A and had a 98 percent NPV for obstructive coronary artery disease.